FINWIRES · TerminalLIVE
FINWIRES
$PFE

$PFE

49 stories mentioning PFEUpdated 20d ago

Every FINWIRES story that references PFE, newest first.

Sectors

Sector Update: Health Care Stocks Edge Higher Late Afternoon

Health care stocks edged up late Tuesday afternoon, with the NYSE Health Care Index fractionally higher and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.2%.The iShares Biotechnology ETF (IBB) declined 0.6%.In sector news, the US Food and Drug Administration plans to pilot an approach this summer that will use AI to accelerate clinical trials of new medicines by automating data collection and submission, The Wall Street Journal reported Tuesday, citing an interview with Jeremy Walsh, the FDA's chief AI officer.In corporate news, Axogen (AXGN) shares jumped past 6% after it reported Tuesday a swing to Q1 adjusted EPS from a a loss a year earlier following a surge in revenue.Pfizer (PFE) said Tuesday it entered into settlement agreements with three generic drug manufacturers regarding lawsuits filed in the US District Court for the District of Delaware for patent infringement related to Vyndamax, a cardiomyopathy transthyretin-mediated amyloidosis treatment. Pfizer shares were down 1.7%.Eli Lilly (LLY) has entered into a strategic partnership with Profluent to develop AI-designed recombinases for genetic medicines, Profluent said Tuesday. Lilly shares rose 0.6%.Novartis (NVS) reported Q1 core earnings Tuesday of $1.99 per share, down from $2.28 a year earlier. Analysts polled by FactSet expected $2.19. Net sales for the quarter ended March 31 were $13.11 billion, down from $13.23 billion a year earlier. For 2026, the company said it continues to expect a low-single-digit core operating income decline. Novartis shares were up 0.3%.

$AXGN$LLY$NVS$PFE
Sectors

Sector Update: Health Care Stocks Edge Higher Tuesday Afternoon

Health care stocks edged up Tuesday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 0.2%.The iShares Biotechnology ETF (IBB) shed 0.6%.In corporate news, Pfizer (PFE) said Tuesday it entered into settlement agreements with three generic drug manufacturers regarding lawsuits filed in the US District Court for the District of Delaware for patent infringement related to Vyndamax, a cardiomyopathy transthyretin-mediated amyloidosis treatment. Pfizer shares were down 0.8%.Eli Lilly (LLY) has entered into a strategic partnership with Profluent to develop AI-designed recombinases for genetic medicines, Profluent said Tuesday. Lilly shares decreased 0.2%.Novartis (NVS) reported Q1 core earnings Tuesday of $1.99 per share, down from $2.28 a year earlier. Analysts polled by FactSet expected $2.19. Net sales for the quarter ended March 31 were $13.11 billion, down from $13.23 billion a year earlier. For 2026, the company said it continues to expect a low-single-digit core operating income decline. Novartis shares were fractionally lower.

$LLY$NVS$PFE
Wire

Citigroup Lifts Price Target on Pfizer to $27 From $26, Maintains Neutral Rating

Pfizer (PFE) has an average rating of hold and mean price target of $28.90, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $26.61, Change: $-0.18, Percent Change: -0.69%

$PFE
Wire

Jefferies Adjusts Price Target on Pfizer to $35 From $34, Maintains Buy Rating

Pfizer (PFE) has an average rating of hold and mean price target of $28.90, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $26.60, Change: $-0.20, Percent Change: -0.73%

$PFE
Wire

Pfizer Reaches Three Settlements in Vyndamax Patent Infringement Suits

Pfizer (PFE) said Tuesday it entered into settlement agreements with three generic drug manufacturers regarding lawsuits filed in the US District Court for the District of Delaware for patent infringement related to Vyndamax, a cardiomyopathy transthyretin-mediated amyloidosis treatment.The settlements extend the drug's effective US patent expiry date to June 1, 2031, subject to the outcome of other litigation, the company said."Pfizer had previously anticipated a significant decline in U.S. revenues for Vyndamax beginning in 2029 upon patent expiry," Pfizer said. "As a result of this settlement, revenues are now expected to remain relatively stable from 2028 through mid-2031."Price: $26.65, Change: $-0.15, Percent Change: -0.54%

$PFE
Wire

Pfizer Reaches Three Settlements in Vyndamax Patent Infringement Suits

Pfizer Reaches Three Settlements in Vyndamax Patent Infringement Suits

$PFE
Wire

Pfizer's Upcoming Tafamidis Bench Trial Shows Asymmetric Upside, RBC Capital Markets Says

Pfizer's (PFE) tafamidis bench trial commencing next week shows an asymmetric upside based on modeling of three core outcome scenarios, creating a $5 billion net present value differential between bear and bull cases, RBC Capital Markets said in a Monday note.The investment firm said the lawsuit hinges on the '441 polymorph patent that is set to expire in 2035 and is "scientifically the weakest," as the '695 compound and '696 method-of-use patents are expected to hold.RBC estimated a 19% probability for a Pfizer win, with the company showing infringement and getting protection through 2035, representing over $6 billion in net present value.There is a 60% probability for a tie, with generics entry from around 2032, representing net present value of over $3 billion, according to the note.Additionally, there's a 21% probability for Pfizer losing the case and its polymorph patent is held as not infringed, translating into 2028 entry of generics, which is currently priced in the company's stock, the firm said.RBC maintained its underperform rating on the stock with a $25 price target.Price: $27.77, Change: $+0.21, Percent Change: +0.74%

$PFE
Research

CICC Initiates Pfizer at Outperform With $33 Price Target

Pfizer (PFE) has an average rating of hold and mean price target of $28.94, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$PFE
Wire

UBS Raises Price Target on Pfizer to $27 From $25, Maintains Neutral Rating

Pfizer (PFE) has an average rating of hold and mean price target of $28.77, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $26.90, Change: $-0.02, Percent Change: -0.07%

$PFE

Showing 41-49 of 49

Track with the FINWIRES app suite

FolioX
FolioX
Track PFE in your portfolio
WheelAI
WheelAI
Analyze PFE options with the wheel strategy
StockInsider
StockInsider
See market sentiment on PFE